News

Now recruiting: Bioinformatics Scientist

Bioinformatics Scientist   Do you want to help usher in advanced cancer diagnostics and monitoring to improve patient quality of life and survival?   SAGA Diagnostics AB is seeking a talented and highly motivated Bioinformatics Scientist with strong interest in advancing our mission to revolutionize cancer diagnostics through proprietary ultrasensitive…

Now recruiting: Medical Laboratory Scientist

Medical Laboratory Scientist in Lund, Sweden SAGA Diagnostics AB is seeking a talented and highly motivated Medical Laboratory Scientist (laboratory technician) with strong interest in advancing our mission to revolutionize cancer diagnostics through proprietary ultrasensitive technologies that measure circulating tumor DNA (ctDNA) in minimally-invasive “liquid biopsies” such as a simple blood sample….

Now recruiting: VP, Clinical Development (FILLED)

VP, Clinical Development   Do you want to help usher in advanced cancer diagnostics and monitoring to improve patient quality of life and survival?   SAGA Diagnostics is seeking a talented and highly motivated VP, Clinical Development with strong interest in advancing our mission to revolutionize cancer diagnostics. Our proprietary…

SAGA Diagnostics enters into Development Agreement with AstraZeneca

  LUND, Sweden — /November 2, 2021/ — SAGA Diagnostics AB, a cancer liquid biopsy and genomic testing company focused on precision oncology and non-invasive ultrasensitive monitoring of cancer patients, has entered into an assay development agreement with the global, science-led biopharmaceutical company AstraZeneca (LSE/STO/Nasdaq: AZN).   SAGA Diagnostics will…

SAGA hires two new scientists to strengthen its R&D Team

LUND, Sweden — /October 28, 2021/ — SAGA Diagnostics AB, (“SAGA”), a cancer liquid biopsy and genomic testing company focused on precision oncology and non-invasive ultrasensitive monitoring of cancer patients, today announces that it has hired two new scientists to significantly strengthen SAGA’s Research and Development Team: Nuria Seguí, PhD as…

Proof of concept SAGAsafe® 24-plex ultrasensitive compatibility demonstrated on naica® Prism 6 dPCR instrument

LUND, Sweden — /October 20, 2021/ — SAGA Diagnostics AB, “SAGA”, a leading cancer liquid biopsy and genomic testing company, adapted a SAGAsafe® PIK3CA 24-plex mutation detection assay to work on Stilla Technologies’ new naica® Prism 6 system which was presented at this year’s Annual Meeting of the American Society…

SAGA Diagnostics appoints Peter Collins as Chief Executive Officer

LUND, Sweden — /October 7, 2021/ — SAGA Diagnostics AB, (“SAGA”), a leading cancer liquid biopsy and genomic testing company, is pleased to announce the appointment of Peter Collins as Chief Executive Officer.   Mr. Collins is a highly experienced entrepreneur with over 30 years of experience in the pharma and diagnostics…

Now recruiting: Bioinformatics Scientist (FILLED)

Bioinformatics Scientist   Do you want to help usher in advanced cancer diagnostics and monitoring to improve patient quality of life and survival?   SAGA Diagnostics AB is seeking a talented and highly motivated Bioinformatics Scientist with strong interest in advancing our mission to revolutionize cancer diagnostics through proprietary ultrasensitive…

SAGA Diagnostics raises SEK 106 million (€10.5 million) to accelerate commercialization of ultrasensitive cancer liquid biopsies

  LUND, Sweden, and STOCKHOLM, Sweden — /June 29, 2021/ — SAGA Diagnostics AB (“SAGA”), a cancer liquid biopsy and genomic testing company, today announced that it has raised SEK 106 million (€10.5 million) in a Series A2 financing from both existing and new investors. The Series A2 round was led…

SAGA expands research collaboration with University College London Cancer Institute

  LUND, Sweden — /June 17, 2021/ — SAGA Diagnostics AB, a cancer liquid biopsy and genomic testing company focused on precision oncology and non-invasive ultrasensitive monitoring of cancer patients, today announced an expanded research collaboration with Professor Charles Swanton, at the University College London (UCL) Cancer Institute.   Last…